Novanta Inc. completed the acquisition of Riverpoint Medical from Arlington Capital Partners on July 23, 2026, for approximately $1.2 billion in cash, with a $250.0 million milestone payment due by January 8, 2027. To fund the transaction, the company borrowed $616.0 million under its revolving credit and delayed draw term loan facilities, bringing its total consolidated debt to $854.7 million. Novanta Inc. is a global supplier of core technology solutions for medical, life science, and advanced industrial original equipment manufacturers.

Novanta Inc. entered into a Securities Purchase Agreement on June 8, 2026, for a private placement of 2,142,857 common shares at $140.00 per share, totaling approximately $300.0 million. The company will also enter into a Registration Rights Agreement to register the resale of these shares within 30 days of the expected June 11, 2026, closing. Novanta Inc. is a provider of advanced precision technologies for medical, industrial, and life science applications.

On June 8, 2026, Novanta Inc. entered into an Equity Purchase Agreement to acquire Runway Buyer, LLC from Runway Midco, LLC for $1.2 billion in cash, with an additional $250 million milestone payment due by January 8, 2027. The transaction is financed via cash on hand, existing credit facilities, and a new equity issuance. To support the acquisition, the company amended its credit agreement with Bank of America, N.A., increasing the permitted consolidated leverage ratio to 4.00:1.00 or 4.50:1.00 for four quarters following the acquisition and decreasing the permitted consolidated fixed charge coverage ratio to 1.00:1.00. Novanta Inc. provides precision instrumentation and photonic components for the medical and industrial markets.